JAK2 V617F mouse liver pathology testing provides researchers with comprehensive histological analysis of hepatic changes in myeloproliferative neoplasm (MPN) models, including extramedullary hematopoiesis, megakaryocyte infiltration, and fibrosis assessment. Our professional pathology platform combines standardized tissue processing, specialized staining techniques, and semi-quantitative scoring systems to deliver reproducible, publication-quality data for preclinical studies. From H&E morphology to reticulin fiber grading and immunohistochemistry, this service supports mechanism research and drug efficacy evaluation in JAK2 V617F-driven disease models.
Technical Overview
The JAK2 V617F mutation is a somatic gain-of-function alteration in the Janus kinase 2 (JAK2) gene that constitutively activates JAK-STAT signaling, driving myeloproliferative neoplasms (MPNs) such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In mouse models harboring this mutation—either through transgenic expression, knock-in strategies, or bone marrow transplantation—the liver serves as a critical target organ for disease monitoring. Because the liver is a major site of extramedullary hematopoiesis (EMH) in MPN models, hepatic pathology directly reflects systemic disease burden, megakaryocyte proliferation, and evolving myelofibrosis.
JAK2 V617F mouse liver pathology testing encompasses a full workflow of tissue collection, fixation, paraffin embedding, microtomy, routine and special staining, immunohistochemistry, and semi-quantitative histological scoring. Key pathological features evaluated include sinusoidal and portal infiltration by hematopoietic precursors, megakaryocyte clusters and dysplasia, reticulin and collagen fiber deposition, sinusoidal dilatation, Kupffer cell activation, and hepatocellular changes. This integrated evaluation provides essential data for phenotyping mutant mice, tracking disease progression, and assessing therapeutic responses to JAK inhibitors and anti-fibrotic agents.
Testing Samples
Transgenic and Knock-In Mouse Liver Tissue
Liver specimens collected from JAK2 V617F transgenic mice or conditional knock-in models (such as Vav1-Cre, Mx1-Cre, or Scl-Cre driven systems) represent the primary sample type. Both heterozygous (Jak2V617F/+) and homozygous (Jak2VF/VF) genotypes are accepted, with wild-type littermates recommended as negative controls to establish baseline hepatic histology.
Bone Marrow Transplant Recipient Livers
Liver tissue from recipient mice transplanted with JAK2 V617F-transduced hematopoietic stem cells is suitable for testing. These samples allow evaluation of transplant-derived EMH and fibrosis development in a controlled time-course design, typically at 4, 8, 12, and 16 weeks post-transplantation.
Treatment Study Specimens
Samples from pharmacological intervention studies, including vehicle controls, JAK inhibitor-treated groups (such as ruxolitinib, fedratinib, or pacritinib), and anti-fibrotic compound groups, are accepted for comparative histological analysis. Paired baseline and endpoint specimens enable longitudinal assessment of therapeutic efficacy.
Sample Requirements
- Fresh liver tissue fixed in 10% neutral buffered formalin at a 10:1 fixative-to-tissue volume ratio for 24 to 48 hours
- Recommended sampling from the left lateral lobe and median lobe to ensure anatomical consistency across animals
- Formalin-fixed paraffin-embedded (FFPE) blocks or 4–5 μm sections on charged slides also accepted
- Accompanying information including genotype, mutant allele burden, age, sex, treatment group, and collection time point
Testing Items
Comprehensive JAK2 V617F mouse liver pathology testing covers morphological, histochemical, and immunohistochemical endpoints, each addressing a distinct aspect of MPN-associated hepatic disease.
- Hematoxylin and eosin (H&E) staining for overall hepatic architecture, EMH foci, megakaryocyte localization, portal inflammation, and hepatocellular morphology
- Reticulin fiber staining (Gordon-Sweets or Gomori silver method) for assessment of fiber density, distribution, and grading of hepatic fibrosis on a semi-quantitative scale
- Masson's trichrome staining for visualization of mature collagen deposition and confirmation of advanced fibrotic changes
- Immunohistochemistry for lineage markers including CD41 or CD42b (megakaryocytes/platelets), Ter119 (erythroid precursors), Ly6G or myeloperoxidase (myeloid cells), F4/80 (Kupffer cells and macrophages), and α-SMA (activated hepatic stellate cells)
- Quantification of extramedullary hematopoiesis including megakaryocyte counts per high-power field, EMH area percentage, and sinusoidal occupancy
- Digital pathology and image analysis for objective quantification of positive staining areas, cell counts, and fibrosis indices
- Optional genotype verification on tissue sections using allele-specific PCR or qPCR to confirm mutant allele burden correlation with histological severity
Testing Methods
Tissue Processing and Sectioning
Fixed liver tissue is trimmed to standardized 3–4 mm thick sections from consistent anatomical locations, processed through graded alcohols, xylene clearing, and paraffin infiltration using an automated tissue processor. Embedded blocks are sectioned at 4–5 μm thickness and mounted on positively charged glass slides. One section is designated for H&E, adjacent sections for special stains, and serial sections for immunohistochemical labeling.
Routine and Special Staining Protocols
H&E staining follows standard dehydration, nuclear staining with hematoxylin, cytoplasmic counterstaining with eosin, and coverslipping. Reticulin staining employs silver impregnation to blacken type III reticular fibers, allowing evaluation of sinusoidal fiber framework disruption and increased fiber density characteristic of myelofibrosis-associated hepatic fibrosis. Masson's trichrome staining delineates blue-staining collagen fibers against red hepatocyte and muscle cytoplasm, confirming mature collagen deposition in portal and perisinusoidal regions.
Immunohistochemistry Workflow
Sections undergo deparaffinization, rehydration, and heat-induced epitope retrieval in citrate or EDTA buffer optimized for each primary antibody. Endogenous peroxidase is blocked with hydrogen peroxide, followed by protein blocking to minimize nonspecific binding. Primary antibodies are incubated according to validated protocols, followed by biotin-free polymer-based secondary detection and DAB chromogen visualization with hematoxylin counterstaining. Known positive and negative control tissues are included in every run to ensure staining specificity and run-to-run consistency.
Scoring and Quantitative Analysis
- Reticulin fibrosis is graded using an adapted semi-quantitative scale from 0 to 4, where grade 0 represents normal sinusoidal fiber pattern and grade 4 represents diffuse dense fiber deposition with architectural distortion
- Megakaryocytes are counted in a minimum of 10 random high-power fields (400×) per section, with results expressed as mean cells per field and categorized by location (sinusoidal, portal, parenchymal)
- EMH burden is quantified as percentage of hepatic parenchyma occupied by hematopoietic cell clusters using whole-slide digital image analysis
- IHC positivity is quantified as positive area fraction or integrated optical density using calibrated digital pathology software, with blinded scoring performed by two independent board-certified veterinary pathologists
- Statistical comparison across genotype and treatment groups is provided with mean, standard deviation, and appropriate significance testing upon request
Quality Control Measures
All procedures follow GLP-aligned standard operating procedures with rigorous internal controls. Staining quality is verified against reference standards before case evaluation, and all glass slides and scanned digital images undergo pathologist review. Archival FFPE blocks and stained slides are retained for a minimum of five years, with whole-slide images available in digital format for remote review and collaborative analysis.
Applications
JAK2 V617F mouse liver pathology testing supports a wide range of preclinical research and drug development applications in hematological disease and hepatic fibrosis research.
- Phenotypic characterization of newly established JAK2 V617F mouse lines, documenting the extent of hepatic EMH and fibrosis relative to disease severity and mutant allele burden
- Efficacy evaluation of JAK inhibitors and novel kinase inhibitors, measuring reduction in hepatic EMH, megakaryocyte burden, and reticulin fibrosis following treatment
- Anti-fibrotic drug development, using reticulin grading and collagen quantification as pharmacodynamic endpoints in myelofibrosis models
- Mechanistic studies of the JAK-STAT signaling pathway in hematopoietic stem cell mobilization, splenomegaly, and hepatic infiltration
- Longitudinal disease progression studies correlating blood counts, spleen weight, serum cytokines, and hepatic histopathology
- Biomarker validation, linking immunohistochemical markers such as p-STAT5, α-SMA, and CD41 expression with clinical chemistry and molecular data
- Regulatory submission support, providing GLP-grade histopathology data packages for IND-enabling toxicity and efficacy studies
- Publication-ready histology, delivering high-resolution images and quantified scoring data suitable for peer-reviewed journals in hematology and pathology
FAQ
Why is the liver specifically examined in JAK2 V617F mouse models?
The liver is a primary organ of extramedullary hematopoiesis in MPN models. When bone marrow is overtaken by clonal proliferation and fibrosis, hematopoiesis shifts to the liver and spleen. Hepatic pathology—including megakaryocyte clusters, hematopoietic infiltration, and secondary fibrosis—directly mirrors systemic disease burden, making the liver a sensitive and informative indicator of disease stage and treatment response.
How is reticulin fibrosis graded in mouse liver sections?
Reticulin fiber density is evaluated using a semi-quantitative four-tier grading system adapted from human myelofibrosis criteria. Grade 0 indicates a normal linear sinusoidal fiber pattern, grade 1 shows focal slightly increased fiber density, grade 2 demonstrates diffuse increased density with fiber branching, grade 3 reveals extensive branching with crossover forming loose networks, and grade 4 represents diffuse dense fibrosis with marked architectural distortion. Grading is performed by blinded pathologists on silver-impregnated sections.
What turnaround time should be expected for testing?
Standard histology packages including H&E, reticulin, and Masson's trichrome staining with scoring reports are typically completed within 7 to 10 business days after sample receipt. Projects involving extended immunohistochemistry panels or digital image quantification may require 10 to 15 business days depending on panel complexity and sample volume.
Can frozen liver tissue be used instead of FFPE samples?
FFPE tissue is strongly recommended because it provides superior morphology for reticulin and trichrome staining and is compatible with most validated IHC antibodies. Frozen sections may be acceptable for select fluorescence-based applications or when phospho-epitopes such as p-STAT5 are targeted, but morphology-based fibrosis grading is less reliable on frozen material and should be discussed with the project pathologist in advance.
How many animals per group are recommended for meaningful statistical comparison?
Based on typical effect sizes in JAK2 V617F models, a minimum of 5 to 8 mice per group is recommended for histological endpoints, with 8 to 10 animals preferred for treatment studies where intra-group variability is expected. Including wild-type littermate controls and, where feasible, baseline sentinel animals strengthens data interpretation.
Is molecular confirmation of the JAK2 V617F mutation available from tissue sections?
Yes. Allele-specific PCR or quantitative PCR can be performed on DNA extracted from FFPE liver sections or from paired hematopoietic tissues to verify genotype and measure mutant allele burden. Correlating allele burden with histological severity adds valuable interpretive depth, particularly in transplantation and mosaic expression models.
What deliverables are included in the final report?
The final report includes stained glass slides, whole-slide digital images, individual animal histopathology descriptions, semi-quantitative scoring tables, group-level statistical summaries, representative photomicrographs at multiple magnifications, and a pathologist-signed interpretive summary. Raw image analysis data are provided in spreadsheet format to support independent statistical analysis by the client.